CVM-1118 for Advanced Neuroendocrine Tumors
Active, Not Recruiting Phase 2 NCT03600233
Study Description
CVM-1118 developed by TaiRx, Inc. is a new anti-cancer therapeutic with high potential for treating advanced Neuroendocrine Tumors (NETs). NETs are uncommon malignancies originating from neuroendocrine cells localized throughout the body which often result in mortality. The formation of vasculogenic mimicry (VM) has been reported in at least two types of NETs and is considered an important therapeutic target. CVM-1118 has a high potential to inhibit VM and is currently being evaluated for its efficacy in treating advanced NETs in phase 2 clinical trials.
Study Details
- Registry ID:
- NCT03600233
- Conditions:
- Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma
- Phase:
- Phase 2
- Target Enrollment:
- 34 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (11 sites)
-
National Cheng Kung University Hospital
Tainan, Taiwan -
Chang Gung Memorial Hospital, KaoHsiung
Kaohsiung, Taiwan -
Kaohsiung Medical University Hospital
Kaohsiung, Taiwan -
Chang Gung Memorial Hospital, KaoHsiung
Kaohsiung City, Taiwan -
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan -
China Medical University Hospital
Taichung, Taiwan -
Taichung Veterans General Hospital
Taichung, Taiwan -
Chang Gung Memorial Hospital, LinKou
Taoyuan City, Taiwan -
Chang Gung Memorial Hospital, LinKou
Taoyuan, Taiwan -
New Taipei Municipal TuCheng Hospital
New Taipei City, Taiwan -
Taipei Veterans General Hospital
Taipei, Taiwan
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.